Marc Riedl is a Rheumatology/Immunology physician affiliated with La Jolla Institute for Immunology. OpenAlex indexes 311 publications with 10,399 citations (h-index 49); ClinicalTrials.gov lists 3 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Allergy & Immunology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8899 University Center Ln Ste 230
San Diego, CA 92122
Telephone
858-657-5350Registry record last updated 18 Oct 2018.
Clinical trials
- Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II
Sponsor: Pharvaris Netherlands B.V.
- 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
Sponsor: BioCryst Pharmaceuticals
- Diesel Exhaust Particles and Leukotriene Production
Sponsor: University of California, Los Angeles
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
24 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- CSL BehringProgram year202523 payments$37,703openpaymentsdata.cms.gov ↗
- Takeda Pharmaceuticals U.S.A., Inc.Program year202515 payments$16,536openpaymentsdata.cms.gov ↗
- Pharming Healthcare, Inc.Program year202510 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
43.4%Plasma Kallikrein Inhibitor18.3%Takhzyro90%Orladeyo10%Part D<11 patientsBradykinin B2 Receptor Antagonist15.3%Icatibant69%Firazyr31%Part D<11 patients+ 1 more class in this area
Respiratory
39.8%Histamine-1 Receptor Antagonist9.3%Azelastine Hcl100%Part D≥18 patientsLeukotriene Receptor Antagonist9.1%Montelukast Sodium100%Part D≥26 patients+ 5 more classes in this area
Metabolism & gastrointestinal
6.2%Corticosteroid4.1%Prednisone100%Part D≥20 patientsH2 blocker2.2%Famotidine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2006–2009 per NIH RePORTER. The latest:
- THE ROLE OF GENES IN DETERMINING THE EFFECT OF DIESEL PARTICLES ON ALLERGIC RESP
University of California Los Angeles
FY2009$3,879M01RR000865 - EFFECT OF BROCCOLI SPROUTS ON PHASE II ENZYMES AND RESPIRATORY OXIDATIVE STRE
University of California Los Angeles
FY2007$38,465M01RR000865 - EFFECT OF BROCCOLI SPROUTS ON PHASE II ENZYMES AND RESPIRATORY OXIDATIVE STRE
University of California Los Angeles
FY2006$48,446M01RR000865
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks
New England Journal of Medicine
2024 - The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update
World Allergy Organization Journal
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Karen Marder, MD
La Jolla Institute for Immunology
Bruce Zuraw, MD
La Jolla Institute for Immunology
Jennifer Dan, MD, PhD
La Jolla Institute for Immunology
Yunichel Joo, MD
La Jolla Institute for Immunology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”